During the past decade, HEMORIO - Unidade de Pesquisa Clínica conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "HEMORIO - Unidade de Pesquisa Clínica" are "Sickle Cell Disease" (2 trials), "Vaso-occlusive Crisis" (2 trials), "Vaso-occlusive Pain Episode in Sickle Cell Disease" (2 trials), "Isocitrate Dehydrogenase" (1 trials) and "Leukemia, Myeloid" (1 trials). Many other conditions were trialed in "HEMORIO - Unidade de Pesquisa Clínica" in a lesser frequency.

Most popular intervention types in "HEMORIO - Unidade de Pesquisa Clínica" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Inclacumab" (2 trials), "AG-221" (1 trials), "Azacitidine" (1 trials) and "BSC" (1 trials). Other intervention names were less common.

The vast majority of trials in "HEMORIO - Unidade de Pesquisa Clínica" are 4 trials for "All" genders.

Currently, there are NaN active trials in "HEMORIO - Unidade de Pesquisa Clínica". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in HEMORIO - Unidade de Pesquisa Clínica, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in HEMORIO - Unidade de Pesquisa Clínica, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".